Literature DB >> 26406136

Quantitative Analysis Versus Visual Assessment of Neuromelanin MR Imaging for the Diagnosis of Parkinson's disease.

Sofia Reimão1,2, Patrícia Pita Lobo3,2, Dulce Neutel3,2, Leonor Correia Guedes3,2, Miguel Coelho3,2, Mario M Rosa3,2, Joana Ferreira4, Daisy Abreu2, Nilza Gonçalves2, Carlos Morgado1, Rita G Nunes4, Jorge Campos1, Joaquim J Ferreira2,5.   

Abstract

BACKGROUND: Specific MR sequences have been able to identify the loss of neuromelanin in the substantia nigra (SN) of early stage Parkinson's disease (PD) patients. Since this technique may have a significant impact in clinical patient management, easy and widely available imaging analysis is needed for routine use.
OBJECTIVE: In this study we compared a quantitative analysis with a visual assessment of SN neuromelanin-sensitive MR images in early stage PD patients, in terms of pattern changes recognition and diagnostic accuracy.
METHODS: The inclusion criteria were untreated "de novo" PD patients or a 2-5 year PD duration; in addition, age matched controls were enrolled. These were studied with a high-resolution T1-weighted MR imaging sequence at 3.0 Tesla to visualize neuromelanin. The primary outcome was the comparison of quantitative width measurement with visual assessment by experienced neuroradiologists of SN neuromelanin sensitive MR images for PD diagnosis.
RESULTS: A total of 12 "de novo" PD patients, 10 PD patients with 2-5 year disease duration and 10 healthy controls were evaluated. We obtained a good accuracy in discriminating early-stage PD patients from controls using either a quantitative width measurement of the T1 high signal or a simple visual image inspection of the SN region.
CONCLUSIONS: Visual inspection of neuromelanin-sensitive MR images by experienced neuroradiologists provides comparable results to quantitative width measurement in the detection of early stage PD SN changes and may become a useful tool in clinical practice.

Entities:  

Keywords:  MRI; Neuromelanin; Parkinson’s disease; locus ceruleus; substantia nigra

Mesh:

Substances:

Year:  2015        PMID: 26406136     DOI: 10.3233/JPD-150551

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  7 in total

1.  Diagnostic performance of neuromelanin-sensitive magnetic resonance imaging for patients with Parkinson's disease and factor analysis for its heterogeneity: a systematic review and meta-analysis.

Authors:  Se Jin Cho; Yun Jung Bae; Jong-Min Kim; Donghyun Kim; Sung Hyun Baik; Leonard Sunwoo; Byung Se Choi; Jae Hyoung Kim
Journal:  Eur Radiol       Date:  2020-09-04       Impact factor: 5.315

2.  The diagnostic value of SNpc using NM-MRI in Parkinson's disease: meta-analysis.

Authors:  Xiangming Wang; Yuehui Zhang; Chen Zhu; Guangzong Li; Jie Kang; Fang Chen; Ling Yang
Journal:  Neurol Sci       Date:  2019-08-07       Impact factor: 3.307

Review 3.  Magnetic resonance imaging for the diagnosis of Parkinson's disease.

Authors:  Beatrice Heim; Florian Krismer; Roberto De Marzi; Klaus Seppi
Journal:  J Neural Transm (Vienna)       Date:  2017-04-04       Impact factor: 3.575

4.  Neuroimaging cerebrovascular biomarkers in Parkinson's disease.

Authors:  Mariana Alves; Patrícia Pita Lobo; Linda Azevedo Kauppila; Leonor Rebordão; M Manuela Cruz; Carla Guerreiro; José M Ferro; Joaquim J Ferreira; Sofia Reimão
Journal:  Neuroradiol J       Date:  2021-12-06

Review 5.  Brain Magnetic Resonance Imaging (MRI) as a Potential Biomarker for Parkinson's Disease (PD).

Authors:  Paul Tuite
Journal:  Brain Sci       Date:  2017-06-16

6.  Quick MR Neuromelanin Imaging Using a Chemical Shift Selective Pulse.

Authors:  Midori Kusama; Noriko Sato; Yukio Kimura; Kenji Miyagi
Journal:  Magn Reson Med Sci       Date:  2020-02-19       Impact factor: 2.471

7.  A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy.

Authors:  Rita Moiron Simões; Ana Castro Caldas; Joana Grilo; Daisy Correia; Carla Guerreiro; Patrícia Pita Lobo; Anabela Valadas; Marguerita Fabbri; Leonor Correia Guedes; Miguel Coelho; Mario Miguel Rosa; Joaquim J Ferreira; Sofia Reimão
Journal:  BMC Neurol       Date:  2020-11-27       Impact factor: 2.474

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.